Cellular Biomedicine Group, Inc.: Cellular Biomedicine Group (NASDAQ: CBMG), a clinical-stage biopharma, will bring the first marketed CAR-T cell therapy, Kymriah, to China (the second largest healthcare market) with its strategic collaboration with Novartis. This validates CBMG's in-house cell manufacturing capabilities developed in partnership with General Electric and Thermo Fisher. CBMG's proprietary immuno-oncology pipeline includes BCMA, CD22, TCR-T for HCC and TIL for the treatment of NSCLC and other solid tumors.
Based in...
Disease Space
Immuno-Oncology, Oncology
Public, USA
Market Cap
100MM - 500MM
1345 Avenue of the Americas
11th Floor
New York, NY 10105
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Hamptons CEO Roundtable 2019

Bridgehampton, August 15, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.